Summary:
Click image to enlarge
Lebrikizumab is currently FDA approved for the treatment of eczema. The purpose of this study is to evaluate the effectiveness of lebrikizumab for the treatment of Perennial Allergic Rhinitis. Duration of participation expected ~ 30 months.
Qualified Participants Must:
• Be at least 18 years old
Have a history of uncontrolled allergy symptoms despite use of nasal steroid sprays now, or in the past
•
Note year-round allergy symptoms, even in winter
•
Have moderate – severe dust mite allergy confirmed by allergy testing
Qualified Participants May Receive:
Study related care and medication at no cost.
Compensation for time and travel involved – up to $5,040.